Drug Discovery · Cambridge, MA · Founded 2020 · Privately Held (backing)
Operator of a clinical-stage biotechnology company intended to explore the full potential of alpha-emitting radioantibodies to treat cancer. Convergent Therapeutics is based in Cambridge, MA and was founded in 2020. Its last known valuation is $280 million. It has raised $130 million across 2 recorded rounds; the latest was a $22.2 million early-stage round in Jul 2024.
Last price · $/share
—
Implied valuation
$280.0M
Total raised
$130.0M
Last round
Early Stage VC
Jul 2024
Team — not yet on record
No current team members for Convergent Therapeutics are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Convergent Therapeutics with a free account
·Watch Convergent Therapeutics: the Monday email on marks, rounds and moves
